Ospedale Niguarda Ca' Granda, best known simply as Ospedale Niguarda or Niguarda Hospital is largest and one of the most important hospitals in Milan, Italy.

During the past decade, Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 17 clinical trials were completed, i.e. on average, 37% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 7 clinical trials were completed. i.e. 31.8% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "ERIC Group" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "GOG Foundation" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia" are "Chronic Lymphocytic Leukemia" (9 trials), "Acute Myeloid Leukemia" (5 trials), "Non-Hodgkin's Lymphoma" (5 trials), "Colorectal Cancer" (3 trials) and "Acute Lymphoid Leukemia" (2 trials). Many other conditions were trialed in "Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia" in a lesser frequency.

Most popular intervention types in "Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia" are "Drug" (55 trials), "Other" (5 trials), "Procedure" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (6 trials), "Rituximab" (6 trials), "Obinutuzumab" (5 trials), "Venetoclax" (5 trials) and "Bevacizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia" are 62 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia". 1 are not yet recruiting, 17 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, 3 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".